Chronic neuropathic pain, epilepsy, depression and anxiety disorders have been
treated successfully with pregabalin. Normal subjects, epileptics and patients with
neuropathic pain to whom pregabalin was prescribed showed an improvement in
objective and subjective sleep parameters. To determine if pregabalin’s sleep
enhancing effect is an independent process, it is necessary to test pregabalin in
primary insomniacs who do not have conditions that could be treated by
pregabalin. My study was designed as a double blind, randomised, crossover,
placebo controlled trial, with 50 milligrams of pregabalin or placebo was
administered for eight consecutive nights. I performed polysomnographic
recordings on eight female chronic primary insomniacs on five nights. Sleep
recordings were performed prior to the intervention, and on the first night and
eighth night of each treatment. Subjects filled out subjective scales at baseline and
night eight of every treatment. While polysomnography and subjective scales
showed that my subjects were insomniac, sleep variables during the pregabalin or
placebo period were unchanged when compared to baseline. A daily dose of 50
mg pregabalin did not have any significant effects on either sleep architecture or
subjective sleep variables in female chronic primary insomniacs.
| Identifer | oai:union.ndltd.org:netd.ac.za/oai:union.ndltd.org:wits/oai:wiredspace.wits.ac.za:10539/14859 |
| Date | 03 July 2014 |
| Creators | Ebrahim, Naseem |
| Source Sets | South African National ETD Portal |
| Language | English |
| Detected Language | English |
| Type | Thesis |
| Format | application/pdf |
Page generated in 0.0021 seconds